10 Biggest Price Target Changes For Monday
SVB Leerink raised Natera, Inc. (NASDAQ: NTRA) price target from $140 to $160. Natera shares fell 0.4% to close at $102.88 on Friday.
Wells Fargo Maintains Overweight on Natera, Raises Price Target to $125
Wells Fargo analyst Dan Leonard maintains Natera (NASDAQ:NTRA) with a Overweight and raises the price target from $110 to $125.
SVB Leerink Maintains Outperform on Natera, Raises Price Target to $160
SVB Leerink analyst Puneet Souda maintains Natera (NASDAQ:NTRA) with a Outperform and raises the price target from $140 to $160.
Natera Reports Centers For Medicare & Medicaid Services Granted Advanced Diagnostic Lab Test Status For Its Signatera Molecular Residual Disease Test
Natera,Inc. (NASDAQ:NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted ADLT status for the Signatera molecular residual
Natera Highlights Publication Of Prospective, Randomized Study Validating Signatera For Prediction Of Immunotherapy Benefit In Nature Journal
Natera,Inc. (NASDAQ:NTRA), a pioneer and global leader in cell-free DNA testing, today announced the publication of a new study in Nature, validating the ability of its personalized and tumor-informed
Raymond James Initiates Coverage On Natera with Market Perform Rating
Raymond James analyst Andrew Cooper initiates coverage on Natera (NASDAQ:NTRA) with a Market Perform rating.
Natera Announces New Prospera Data At ATC 2021 Virtual Connect Conference
Natera, Inc. (NASDAQ:NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it will present new data on its latest scientific innovations in cfDNA testing at the American
Natera Calls Advertising Claim Against Guardant ‘Meritless Suit,’ ‘Misleading’
-- Natera, Inc. (NASDAQ:NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it has been sued by Guardant Health, in an attempt to stop Natera from exposing Guardant
Expert Ratings for Natera
Analysts have provided the following ratings for Natera (NASDAQ:NTRA) within the last quarter:
Last 30 Days
1 Month Ago
2 Months Ago